Titlebook: ;

空隙

书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives影响因子(影响力)




书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives影响因子(影响力)学科排名




书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives网络公开度




书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives网络公开度学科排名




书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives被引频次




书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives被引频次学科排名




书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives年度引用




书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives年度引用学科排名




书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives读者反馈




书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives读者反馈学科排名

简洁

FIN

euphoria

Interim Evaluation of Efficacy in Clinical Trials with Two Primary Endpoints,wo interventions based on two primary endpoints. In this situation, there are many procedures for controlling the Type I error rate. We discuss the simplest procedure, i.e., the weighted Bonferroni procedure which is commonly applied in practice. We evaluate the behavior of the sample size, power, a

爆炸

B-cell

Future Developments,her design features. This includes clinical trials with more than two interventions (e.g., dose-selection clinical trials): trials with time-to-event endpoints and trials with targeted subgroups and enrichment clinical trial designs. In Chap. ., we briefly discuss the issues in the design of these t

B-cell

平息

MENT

Philanthropy and Settler Colonialismuss several decision-making frameworks for evaluating efficacy or futility based on boundaries using group-sequential methodology. We incorporate the correlations among the endpoints into the calculations for futility critical boundaries and evaluate the required sample sizes as a function of design

FICE